Talimogene Laherparepvec (T-VEC)

DRUG4 trials

Conditions

BRAF Gene MutationBasal Cell CarcinomaCutaneous AngiosarcomaCutaneous LymphomaEpithelioid SarcomaMelanoma (Skin)Melanoma Stage IIIb-IVM1aMelanoma and Sarcoma

Phase 1

T-VEC in Non-melanoma Skin Cancer

CompletedNCT03458117

University of ZurichBasal Cell Carcinoma, Cutaneous Lymphoma, Merkel Cell Carcinoma +2

Start: 2018-04-19End: 2022-03-15Updated: 2022-03-18

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

CompletedNCT03555032

Royal Marsden NHS Foundation TrustMelanoma and Sarcoma

Start: 2018-06-26End: 2021-08-01Updated: 2021-08-18

Phase 2

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruitingNCT03069378

Memorial Sloan Kettering Cancer CenterCutaneous Angiosarcoma, Epithelioid Sarcoma, Sarcoma

Start: 2017-03-03End: 2027-03-01Updated: 2026-07-17

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

WithdrawnNCT03972046

TriHealth Inc.BRAF Gene Mutation, Melanoma (Skin), Melanoma Stage IIIb-IVM1a +2

Start: 2019-06-24End: 2020-02-03Updated: 2020-10-19

Journal of Clinical Oncology2023-06-018 citations

Intralesional oncolytic virotherapy with talimogene laherparepvec in patients with cutaneous lymphomas and non-melanoma skin cancers.

Journal of Clinical Oncology2023-06-014 citations

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

JAMA Oncology2020-01-23196 citations

A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.

Journal of Clinical Oncology2018-05-208 citations

Talimogene Laherparepvec (T-VEC)

Sponsors

Conditions

Phase 1

Phase 2

Related Papers